Why Canada is Becoming a Hub for Psychedelics Research and Development
FN Media Group Presents Microsmallcap.com Market Commentary
News provided by
Share this article
Share this article
NEW YORK, March 17, 2021 /PRNewswire/ Canada has become home to some of the most important research and development happening today in the mental health and wellness space. Psychedelic therapy emerged as a breakthrough mental health treatment, and Canadian companies are leading the way in developing psychedelics into safe, effective, and evidence-based treatments. Alongside leading Canadian research organizations like the Multidisciplinary Association for Psychedelic Studies (MAPS), Canadian companies like
Numinus Wellness Inc. (TSXV:NUMI) (OTCPK:LKYSF),
This article was originally published on Microdose Psychedelic Insights, and appears here with permission.
Recent figures estimate that the abuse of tobacco, alcohol, and drugs within the United States totals to over $1 trillion dollars a year in costs and counting.1 Between the. Read More.
Microdose Psychedelic Insights is pleased to present our first custom event series, leveraging the platform strengths of our Psychedelic Operating System.
Mydecine Speakers Series: Psychedelic Innovations is a virtual event that will explore how current research is igniting mainstream medical interest to unlock the potential of psychedelic therapies. We invite you to join us as we explore the incredible findings around current psychedelic research and potential paths to mainstream acceptance. Grab your
free tickets today and join us Dec. 15th from 12:00 – 1:30 pm EST.
Expert Panelists, Fantastic Perspectives
Panelists will be asked to reflect on the past, present, and future potential of the psychedelic space in relation to the mental health crisis. Mydecine Innovation Group‘s very own Robert Roscow (Chief Scientific Officer & Co-Founder), Dr. Rakesh (Chief Medical Officer), and Dr. Robin Carhart-Harris (Scientific Advisory Board Member) will all be speaking.